Dr. Kelly has authored over 220 peer-reviewed publications published in prominent scientific journals including Science, Nature, Cell, New England Journal of Medicine, Proceedings of the National Academy of Sciences, Journal of the American Chemical Society, Biochemistry, and Journal of Medicinal Chemistry. For reprint requests, please click here.
2012:
- Bulawa CE, Connelly S, DeVit M, Wang L, Weigel C, Fleming J, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R. Tafamidis, A Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid CascadeProc. Natl. Acad. Sci. 2012; 109:9629-9634.
- Coelho T, Maia LF, Martins da Silva A, Cruz MW, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceiçao I, Schmidt H, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79:785-792.
- Solomon JP, Page LJ, Balch WE, Kelly JW. Gelsolin Amyloidosis: Genetics, Biochemistry, Pathology and Possible Strategies for Therapeutic Intervention. Crit. Rev. Biochem. Mol. Biol. 2012; 47:282-296.
- Price JL, Culyba EK, Chen W, Murray A, Hanson SR, Wong C-H, Powers ET, Kelly JW. N-glycosylation of the Enhanced Aromatic Sequon to Increase Glycoprotein Stability. Biopolymers 2012; 98:195-211.
- Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory Agency Approved Drug. J. Mol. Biol.2012; 421:185-203.
- Hulleman JD, Balch WE, Kelly JW. Translational Attenuation Differentially Alters the Fate of Disease-associated Fibulin Proteins. FASEB J. 2012 epub:.
